Active Ingredient History
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Allergy and Immunology (Phase 2)
Antigens, CD (Phase 1)
Antiphospholipid Syndrome (Phase 2/Phase 3)
Arthritis, Rheumatoid (Phase 2)
Cryoglobulinemia (Phase 2)
Emphysema (Phase 2)
Glomerulonephritis, Membranous (Phase 2)
Graft vs Host Disease (Phase 1/Phase 2)
Granulomatosis with Polyangiitis (Phase 2)
Healthy Volunteers (Phase 1)
Immunoglobulin G4-Related Disease (Phase 4)
Kidney Transplantation (Phase 1/Phase 2)
Leukemia, Lymphoid (Phase 2)
Lupus Nephritis (Phase 3)
Multiple Sclerosis (Phase 2)
Myasthenia Gravis (Phase 2)
Myositis (Phase 2/Phase 3)
Neoadjuvant Therapy (Phase 2)
Nephrotic Syndrome (Phase 2)
Neuromyelitis Optica (Phase 1/Phase 2)
Organ Transplantation (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Purpura (Phase 2)
Remission Induction (Phase 3)
Scleroderma, Systemic (Phase 2/Phase 3)
Sjogren's Syndrome (Phase 2)
Thrombocytopenia (Phase 3)
Vasculitis (Phase 3)
Waldenstrom Macroglobulinemia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
